doi: 10.1016/0008-8749(86)90108-5.
T-cell depletion of allogeneic bone marrow prevents acceleration of graft-versus-host disease induced by exogenous interleukin 2
- PMID: 3542238
- DOI: 10.1016/0008-8749(86)90108-5
Item in Clipboard
T-cell depletion of allogeneic bone marrow prevents acceleration of graft-versus-host disease induced by exogenous interleukin 2
Cell Immunol.
1986 Dec.
Abstract
Highly purified human recombinant interleukin 2 (IL-2) markedly accelerated lethal GVHD in the H-2-identical B10.BR----CBA combination, but had no effect when the donor cells were depleted of mature (Thy-1.2-positive) T lymphocytes, indicating a strong immunopotentiating effect of IL-2 on mature T cells causing GVHD. In the same donor-host combination, IL-2 did not influence the recovery from the post-transplantation bone marrow aplasia. The results suggest that IL-2 could be considered for adjuvant hormonal therapy to enhance immune recovery in recipients of T-cell-depleted allogeneic marrow.
Similar articles
-
Effect of selective T cell depletion of host and/or donor bone marrow on lymphopoietic repopulation, tolerance, and graft-vs-host disease in mixed allogeneic chimeras (B10 + B10.D2----B10).J Immunol. 1986 Jan;136(1):28-33. J Immunol. 1986. PMID: 2933464
-
Effective graft-versus-leukemia effects independent of graft-versus-host disease after T cell-depleted allogeneic bone marrow transplantation in a murine model of B cell leukemia/lymphoma. Role of cell therapy and recombinant IL-2.J Immunol. 1994 Sep 15;153(6):2562-7. J Immunol. 1994. PMID: 8077666
-
Selective elimination of alloreactive donor T cells attenuates graft-versus-host disease and enhances T-cell reconstitution.Biol Blood Marrow Transplant. 2003 Dec;9(12):742-52. doi: 10.1016/j.bbmt.2003.09.007. Biol Blood Marrow Transplant. 2003. PMID: 14677113
-
Achieving alloengraftment without graft-versus-host disease: approaches using mixed allogeneic bone marrow transplantation.Bone Marrow Transplant. 1988 Sep;3(5):379-86. Bone Marrow Transplant. 1988. PMID: 3056545 Review.
-
Reconstructing immunity after allogeneic transplantation.Immunol Res. 2004;29(1-3):269-82. doi: 10.1385/IR:29:1-3:269. Immunol Res. 2004. PMID: 15181288 Review.
Cited by
-
Medawar and the immunological paradox of pregnancy: in context.Oxf Open Immunol. 2020 Dec 14;2(1):iqaa006. doi: 10.1093/oxfimm/iqaa006. eCollection 2021. Oxf Open Immunol. 2020. PMID: 36845570 Free PMC article.
-
Is human cell therapy research caught in a mousetrap?Mol Ther. 2011 Feb;19(2):224-7. doi: 10.1038/mt.2010.304. Mol Ther. 2011. PMID: 21289634 Free PMC article. No abstract available.
-
Increased lymphokine activated killer (LAK) activity in the regional lymph nodes of mice following immunization with contact sensitizing agents.Clin Exp Immunol. 1987 Oct;70(1):217-21. Clin Exp Immunol. 1987. PMID: 3500814 Free PMC article.
-
Graft-versus-host disease and the Th1/Th2 paradigm.Immunol Res. 1996;15(1):50-73. doi: 10.1007/BF02918284. Immunol Res. 1996. PMID: 8739565 Review.
-
Insights into the role of the JAK/STAT signaling pathway in graft-versus-host disease.Ther Adv Hematol. 2020 Jun 2;11:2040620720914489. doi: 10.1177/2040620720914489. eCollection 2020. Ther Adv Hematol. 2020. PMID: 32537114 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous
